Abstract:Target-based screening is one of the major approaches in drug discovery. Besides the intended target, unexpected drug off-target interactions often occur, and many of them have not been recognized and characterized. The off-target interactions can be responsible for either therapeutic or side effects. Thus, identifying the genome-wide off-targets of lead compounds or existing drugs will be critical for designing effective and safe drugs, and providing new opportunities for drug repurposing. Although many computational methods have been developed to predict drug-target interactions, they are either less accurate than the one that we are proposing here or computationally too intensive, thereby limiting their capability for large-scale off-target identification. In addition, the performances of most machine learning based algorithms have been mainly evaluated to predict off-target interactions in the same gene family for hundreds of chemicals. It is not clear how these algorithms perform in terms of detecting off-targets across gene families on a proteome scale. Here, we are presenting a fast and accurate off-target prediction method, REMAP, which is based on a dual regularized one-class collaborative filtering algorithm, to explore continuous chemical space, protein space, and their interactome on a large scale. When tested in a reliable, extensive, and cross-gene family benchmark, REMAP outperforms the state-of-the-art methods. Furthermore, REMAP is highly scalable. It can screen a dataset of 200 thousands chemicals against 20 thousands proteins within 2 hours. Using the reconstructed genome-wide target profile as the fingerprint of a chemical compound, we predicted that seven FDA-approved drugs can be repurposed as novel anti-cancer therapies. The anti-cancer activity of six of them is supported by experimental evidences. Thus, REMAP is a valuable addition to the existing in silico toolbox for drug target identification, drug repurposing, phenotypic screening, and side effect prediction. The software and benchmark are available at https://github.com/hansaimlim/REMAP.

Deciding when to stop: Efficient stopping of active learning guided drug-target prediction

A Method for Stopping Active Learning Based on Stabilizing Predictions and the Need for User-Adjustable Stopping

How to actively learn chemical reactions yields in real-time using stopping criteria

Analysis of Stopping Active Learning based on Stabilizing Predictions

Efficient Biological Data Acquisition through Inference Set Design

Finding the most potent compounds using active learning on molecular pairs

The SAFE procedure: a practical stopping heuristic for active learning-based screening in systematic reviews and meta-analyses

Iterative Experimental Design Based on Active Machine Learning Reduces the Experimental Burden Associated with Reaction Screening

Toward more realistic drug-target interaction predictions

Targeted Active Learning for Bayesian Decision-Making

A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery

Traversing Chemical Space with Active Deep Learning: A Computational Framework for Low-data Drug Discovery

Stopping Criterion for Active Learning Based on Error Stability

Clinical Advancement Forecasting

Drug Target Identification with Machine Learning: How to Choose Negative Examples

Stopping Criterion for Active Learning with Model Stability.

Predicting drug-target interactions using matrix factorization with self-paced learning and dual similarity information

Invasive or More Direct Measurements Can Provide an Objective Early-Stopping Ceiling for Training Deep Neural Networks on Non-invasive or Less-Direct Biomedical Data

Sequential Design for Optimal Stopping Problems

Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition

Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing.